Charles May, MD
Psychiatry · Knoxville, TNNPI 1245268531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$994
- Ironshore Pharmaceuticals Inc.$733
- Neurocrine Biosciences, Inc.$702
- Takeda Pharmaceuticals U.S.A., Inc.$678
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$657
- plus $5K from 23 others
What the payments were for
- Food & beverage$9,351100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 57 | $1,095 |
| AbbVie(2 entities) | 71 | $994 |
| Ironshore Pharmaceuticals Inc. | 36 | $733 |
| Neurocrine Biosciences, Inc. | 35 | $702 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $678 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $657 |
| Corium, LLC | 26 | $630 |
| Johnson & Johnson | 29 | $606 |
| Sunovion Pharmaceuticals Inc. | 22 | $442 |
| Axsome Therapeutics, Inc. | 20 | $431 |
| Vanda Pharmaceuticals Inc. | 14 | $409 |
| Teva Pharmaceuticals USA, Inc. | 19 | $353 |
| Lundbeck LLC | 17 | $280 |
| Alkermes, Inc. | 16 | $258 |
| Supernus Pharmaceuticals, Inc. | 11 | $202 |
| Tris Pharma Inc | 9 | $160 |
| Almatica Pharma LLC | 8 | $127 |
| Adlon Therapeutics L.p. | 6 | $106 |
| Bausch Health US, LLC | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Neos Therapeutics, LP | 6 | $89 |
| Eisai Inc. | 5 | $76 |
| Shire North American Group Inc | 4 | $60 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Neuronetics, Inc. | 2 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
How this compares
$9,398 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 56 | $24,904 |
| TrintellixVortioxetine Hydrobromide | 19 | $13,929 |
| Olanzapine | 67 | $5,176 |
| Bupropion XlBupropion Hcl | 227 | $5,118 |
| Duloxetine Hcl | 176 | $3,559 |
| Aripiprazole | 102 | $3,082 |
| Quetiapine Fumarate | 162 | $3,012 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 101 | $2,979 |
| Doxepin Hcl | 47 | $2,876 |
| Asenapine Maleate | 18 | $2,328 |
| Alprazolam | 488 | $2,243 |
| Trazodone Hcl | 164 | $2,105 |
| Ziprasidone Hcl | 31 | $2,010 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 72 | $1,750 |
| Lamotrigine | 139 | $1,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $678 | $38,83375 claims |
| Almatica Pharma LLCSertraline Hcl | $127 | $68566 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Knoxville
- Karthi NamasivayamKnoxville$225K
- Lane CookKnoxville$53K
- Kelley WalkerKnoxville$17K
- Sharon BurnsideKnoxville$16K
- James KennedyKnoxville$15K
- Bryan WestKnoxville$15K
- Kris HouserKnoxville$14K
- Julia WoodKnoxville$6K
- James RigellKnoxville$6K
- Rakesh AminNashville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.